-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Sign up for news updates
liquid biopsy
-
Cell-free RNA Affords Another Tool in Lung Cancer Diagnosis and Treatment Monitoring
Although cell-free DNA (cfDNA) has emerged as the favored nucleic acid to analyze in liquid biopsy samples, there are situations when this marker fails to provided necessary information. In such cases, cell-free RNA (cfRNA) might help fill the void. “Evaluating RNA in liquid biopsies is important because it can be useful for diagnostic, treatment-prediction, or even prognostic purposes,” according to Luis Raez, MD, of the Memorial…
-
ctDNA Offers a Window Into Emerging Mechanisms of Resistance to Targeted Therapy
Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight into the complexity of a patient’s disease and enabling precision treatment. “Tremendous progress has been made, and I think we are really improving our ability to deliver targeted therapy based on improvements in…
-
Dr. Christian Rolfo Previews the New IASLC Consensus Statement on Liquid Biopsy
In his keynote address during the IASLC 2020 Hot Topic Meeting: Liquid Biopsy, co-chair Christian Rolfo, MD, PhD, MBA, provided an overview of the fastpaced evolution of liquid biopsy. In 2018, at the time of initial discussions, it was only used for treatment-naive patients for whom tissue biopsy was insufficient or after acquired resistance to first- or second-generation EGFR TKIs. Since then groundbreaking research articles…
-
FDA Perspectives on the Use of Liquid Biopsy in NSCLC
The US Food and Drug Administration (FDA) recognizes the value of liquid biopsy in managing patients with cancer, and the agency is actively working to bring these assays to the clinic. Harpreet Singh, MD, Director of the Division of Oncology 2, shed light on past FDA efforts related to approval of liquid biopsy technologies as well as those currently underway. “Liquid biopsies for cancer require close interaction between the oncologist…
-
Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits
Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. In the following interview, Martin Filipits, PhD, discusses liquid biopsy’s role in marker identification and the downstream effects of its use. Dr. Filipits is a…
-
Novel Insights on ctDNA Dynamics During Targeted Therapy and Immune Checkpoint Blockage in NSCLC
By Christian Rolfo, MD, PhD, MBA, Dr.h.c. Posted: December 11, 2019 IN REFERENCE TO: Phallen J, Leal A, Woodward BD, et al. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2019;79(6):1204-1213. Anagnostou V, Forde PM, White JR, et al. Dynamics of Tumor and Immune Responses during Immune Checkpoint…
-
Experts Discuss Turnaround Times, Geographic Differences Regarding Liquid Biopsy
Improved Turnaround Times for Biopsy Results Matters More Than Type of Biopsy By Dr. Edgardo S. Santos Castillero, MD, FACP Posted: December 11, 2019 Dr. Edgardo S. Santos Castillero Regarding “Liquid Biopsy for Assessing Response or Progression in Advanced NSCLC” by Dr. Geoffrey R. Oxnard published in the October issue of the IASLC Lung Cancer News, I…
View ILCN Archives
Provider Resources
Popular Articles